首页> 外文期刊>Techniques in coloproctology >Different segmental transit times in patients with irritable bowel syndrome and 'normal' colonic transit time: is there a correlation with symptoms?
【24h】

Different segmental transit times in patients with irritable bowel syndrome and 'normal' colonic transit time: is there a correlation with symptoms?

机译:肠易激综合征和“正常”结肠转运时间的患者不同的分段转运时间:与症状是否相关?

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: The Rome criteria serve as gold standard for establishing a diagnosis of irritable bowel syndrome (IBS), but only represent a cluster of symptoms. On the other hand, measurement of colonic transit time (CTT) with radiopaque markers is a solid and more objective method to quantify functional abnormalities. The goal of this study was to investigate whether the IBS symptoms, as defined in the Rome II criteria, correspond to objective physiological parameters, i.e. CCTs. METHODS: The study enrolled 148 healthy control subjects and 1385 consecutive IBS patients. Transit times were measured for the whole rectocolon (overall CTT) and for 3 segments (right colon, left colon, rectosigmoid area); segmental distribution of markers and diffusion coefficients were also assessed. In order to analyze homogeneous groups, we restricted analysis to subjects with "normal" CTT (< or =70 hours). RESULTS: Six hundred forty four IBS patients (46%) and 14 control subjects (9%) had CTT >70 h and were eliminated. Insubjects with CTT < or =70 h, CTT did not follow a normal (Gaussian) distribution. We identified 3 different CTT clusters in healthy controls and 4 clusters in IBS patients. Even if CTT was not significantly different between clusters, each cluster was characterized by a specific pattern of segmental colonic transit. There was a marked gender difference: women had longer overall CTT values than men, both in control and IBS patient groups (p<0.001). However, female IBS patients had significantly shorter colorectal transit times than female controls (p<0.001), as well as faster transit than in men through the left colon and rectosigmoid area. There were no significant differences in transit time between male IBS patients and male controls with the exception of a faster rectal transit in IBS patients (p<0.01). There was no association between segmental colonic transit values and sign or symptoms comprising the Rome II criteria. CONCLUSIONS: In subjects with CTT < or =70 h, CTT does not follow a normal distribution but is clustered in subgroups that can be distinguished only by measuring segmental colonic transit. Within these subgroups, there is a marked difference in transit times between IBS patients and normal subjects, suggesting that IBS patients with "normal" CTT are not "normal". The Rome II criteria do not reflect differences in segmental transit times in IBS patients with "normal" CTT. We therefore propose to evaluate segmental transit times in IBS patients with "normal" CTT, before and after treatment, in order to correctly interpretate variations in signs and symptoms. These findings have important implications in evaluating the effect of drugs on bowel function and should help define better inclusion criteria for studies evaluating new drugs for the treatment of IBS.
机译:背景:罗马标准是建立肠易激综合症(IBS)诊断的金标准,但仅代表一系列症状。另一方面,用不透射线标记物测量结肠渡越时间(CTT)是量化功能异常的可靠且客观的方法。这项研究的目的是调查罗马II标准中定义的IBS症状是否对应于客观的生理参数,即CCT。方法:该研究招募了148名健康对照者和1385名连续IBS患者。测量整个直肠结肠(总体CTT)和3个部分(右结肠,左结肠,直肠乙状结肠区域)的转运时间。还评估了标记的分段分布和扩散系数。为了分析同类组,我们将分析限制为具有“正常” CTT(<或= 70小时)的受试者。结果:644例IBS患者(46%)和14例对照受试者(9%)的CTT> 70 h并被排除。在CTT <或= 70 h的受试者中,CTT没有遵循正态(高斯)分布。我们在健康对照中鉴定了3个不同的CTT簇,在IBS患者中鉴定了4个簇。即使各簇之间的CTT没有显着差异,每个簇的特征仍是节段性结肠转运的特定模式。性别之间存在明显差异:在对照组和IBS患者组中,女性的总体CTT值均比男性长(p <0.001)。然而,女性IBS患者的结肠直肠癌转移时间明显短于女性对照组(p <0.001),并且比男性通过左结肠和直肠乙状结肠区域的转移更快。男性IBS患者和男性对照之间的转移时间没有显着差异,除了IBS患者的直肠转移更快(p <0.01)。节段结肠转运值与构成罗马II标准的体征或症状之间没有关联。结论:在CTT <或= 70 h的受试者中,CTT不遵循正态分布,而是聚集在只能通过测量节段性结肠转运来区分的亚组中。在这些亚组中,IBS患者与正常受试者之间的转运时间存在显着差异,这表明具有“正常” CTT的IBS患者并非“正常”。 Rome II标准不能反映CTT为“正常”的IBS患者的节段通过时间的差异。因此,我们建议在治疗之前和之后评估CTT为“正常”的IBS患者的分段转运时间,以便正确解释体征和症状的变化。这些发现对评估药物对肠功能的影响具有重要意义,并且应有助于为评估用于治疗IBS的新药物的研究确定更好的纳入标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号